Document is current

Article History

Received: 29 December 2020

Accepted: 26 May 2021

First Online: 16 July 2021

Declarations

:

: The procedures followed for this study were in accordance with the French Law 78–17 of 6 January 1978 and its later amendments and the General Data Protection Regulation.The study was conducted in accordance with Good Epidemiological Practices.Our satisfaction survey (Market Research) is not qualified as a research involving the human person and does not fall within the scope of the article L1121–1 (ExternalRef removed), modified by the decree n°2017–884 (ExternalRef removed).Thus, the satisfaction survey is apart from any submission to a French ethic committee (Comité de Protection des Personnes, CPP) and to the French health authority (ANSM), as mentioned by the article L1123–8 (ExternalRef removed).Informed consent was obtained from all participants. Before their inclusion in the study, all patients were informed about the aim, method and duration of the study and have consented expressly and specifically to the collection, handling and storage of their personal and health data. All participants were free to withdraw from the study at any time without notice or reason.

: Not applicable.

: TP has received consulting/conference fee from AbbVie, Biogen, BMS, Chugai, Gilead, Fresenius Kabi, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB.HS has received consulting/conference fee from Enterome, Ferring, Fresenius, Amgen, MSD, BMS, Takeda, Biocodex, Pfizer, Sanofi, Janssen, Astellas, Gilead, Danone, Roche, BiomX, Adare, Eligo. Co-founder of Exceliom Bioscience.BH has received consulting/conference fee from Celgene, Leo Pharma, Lilly and Fresenius Kabi.GP and MB are Fresenius Kabi France employees.EP and DT are Carenity employees.